Pre-made Bivatuzumab benchmark antibody (Whole mAb, anti-CD44 therapeutic antibody, Anti-CDW44/CSPG8/ECMR-III/HCELL/HUTCH-I/IN/LHR/MC56/MDU2/MDU3/MIC4/Pgp1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-763

Anti-CD44 therapeutic antibody (Pre-made Bivatuzumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6.[1][2]

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-763-1mg 1mg 3090
GMP-Bios-INN-763-10mg 10mg Inquiry
GMP-Bios-INN-763-100mg 100mg Inquiry
GMP-Bios-INN-763-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Bivatuzumab Biosimilar, Whole Mab, Anti-Cd44 Antibody: Anti-CDW44/CSPG8/ECMR-III/HCELL/HUTCH-I/IN/LHR/MC56/MDU2/MDU3/MIC4/Pgp1 therapeutic antibody
INN Name Bivatuzumab
TargetCD44
FormatWhole mAb
DerivationHumanized
Species Reactivityhuman
CH1 IsotypeIgG1 - kappa
VD LCIgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesBoehringer Ingelheim Pharmaceuticals (Ridgefield CT USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0